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coverage is compromised in the region of PlanSMPCM 
(yellow).  
Table 1: Comparison of VMAT S-IMRT and Do-IMRT plan dose-
volume statistics for PlanPTVs (edited 5mm from body 
surface and excluding PlanPTV_6500 from PlanPTV_5400), 
spinal cord, brainstem, contralateral (CL) and ipsilateral (IL) 
parotids, PlanSMPCM and PlanIPCM. 
 
 
 
Conclusion: Do-IMRT can be achieved using VMAT for the 
DARS trial. Fixed-field IMRT may also be used to reduce 
constrictor dose, however is unlikely to produce plans 
acceptable within the DARS trial QA guidelines. 
 
PO-0859  
Quantifying and categorizing plan rejections as a part of 
the clinical process improvement 
C. Speirs
1Washington University Medical Center, Radiation Oncology, 
St. Louis, USA 
1, J. LaBrash1, S. Mutic1, Y. Rao1, S. Rehman1, M.C. 
Roach1, J.M. Michalski1, S.M. Perkins1 
 
Purpose or Objective: RT plan rejections are defects that 
cause suboptimal or erroneous treatments if undetected and 
should be a focus of improvement. Applying the DMAIIC 
(Define, Measure, Analyze, Improve, Implement, and Control) 
formalism to clinic workflow provides actionable parameters 
for feedback and process correction. In our clinic, a web-
based treatment planning board shows the real-time 
workflow and compiles causes of plan rejection, which can 
be categorized and quantified for subsequent process 
improvement efforts. 
 
Material and Methods: Data was collected from July 2014-
September 2015. 341 (of 673) entries associated with plan 
rejection were categorized as changes in one of the 
following: (1) tumor anatomy/patient setup; (2) 
dose/volume; (3) tumor/OAR constraints; (4) treatment 
planning modification generated during plan review; and (5) 
external (patient-, disease-, or hospital/equipment-
generated) causes. Each entry was initiated by the physician, 
physicist, or dosimetrist involved in planning. Analyzed time 
intervals included the following: (1) dosimetry contours; (2) 
MD contour approval; (3) dosimetry plan computed; (4) 
physics plan precheck; (5) MD plan approval; and (6) total 
time for planning from simulation/planning board entry until 
MD plan approval (TMD). The data was analyzed with Two-
way ANOVA, Student T-test, and Pearson correlation. 
 
Results: The mean TMD time was 85 hrs (+/- 45). With 
breakdown by interval, the mean dosimetry contour (16 hrs), 
MD contour approval (27 hrs), dosimetry planning (12 hrs), 
physics precheck (4 hrs), and MD approval (11 hrs) times were 
calculated. The planning modification category was a 
significant source of variation in planning time (p<0.0001). 
Treatment planning modifications presented the predominant 
(50%) source of planning delay, followed by constraint (26%), 
dose/volume (18%), external (4%), and tumor 
anatomy/patient setup changes (2%). Those with tumor 
anatomy/patient setup or dose/volume changes resulted in 
the longest TMD, dosimetry contour, dosimetry plan 
computing, and MD plan approval intervals. 27% of plan 
modifications were initiated by physicians, 70% by physicists, 
and 3% by dosimetrists. Entries initiated by physicians on the 
planning board were associated with shorter TMD times than 
when physicists initiated plan rejection (p=0.016). 
 
Conclusion: We report a novel process for quantification of 
clinical RT plan rejections. In this analysis, tumor 
anatomy/patient setup or dose/volume changes resulted in 
the longest treatment TMD times. Physician-initiated plan 
modification entries were associated with shorter TMD times, 
which may denote early, proactive involvement—an optimal 
approach with complicated or aggressive disease. Though 
planning delays may depend on department infrastructure 
and patient population, our method provides a 
comprehensive census to optimize planning throughput and 
can be applied as a part of broader process improvement. 
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Purpose or Objective: Craniospinal irradiation is performed 
rarely in a palliative intention due to concerns of acute 
toxicities (mostly dysphaghia and bone marrow supression). 
Therefore the purpose of this study was to evaluate the 
dosimetric parameters responsible for the acute toxicity in 
patients with leptomeningeal metastasis of a solid cancer 
treated with craniospinal irradiation (CSI) by helical 
tomotherapy (HT), 3D conformal radiotherapy (3D-CRT) and 
Protons. 
 
Material and Methods: Data of five adult patients previously 
treated with HT CSI were evaluated. For each patient the 
initial tomotherapy plan (inHT) was compared to a 3D 
conformal plan (3D-CRT), a scanning proton beam plan (p-
CSI) as well as to a specifically optimized bone marrow (BM) 
sparing tomotherapy plan (BM-HT). The BM-HT was also 
optimized to reduce the acute dysphagia. The prescribed 
dose was 36 Gy. All active bone marrow compartments were 
delineated separately according to Campbell et al. To 
analyse the impact of different bone marrow compartments 
weighted bone marrow exposure (WBME) was used. 
WBME Dmean =Σ(proportion (%) of functional bone marrow 
according to anatomical site x Dmean to anatomical site)  
WBME V20=Σ(proportion (%) of functional bone marrow 
according to anatomical site x V20 to anatomical site)  
This calculation was also performed for V30. 
Further, the following organ at risks (OARs) were delineated: 
left and right submandibular glands, the parotid glands, the 
eyes, the cochlea, the oral cavity, the pharynx, the thyroid 
gland, the esophagus, the heart, both lungs, both kidneys, 
the liver, the bowel, and the pancreas. For all of these 
structures the Dmean in all four treatment plans were 
analyzed. 
Descriptive statistics were used to analyze the results. 
 
Results: p-CSI results in the best sparing of the organs at risk 
(OARs) including the active bone marrow compartments. BM-
HT achieved better results as inHT and 3D-CRT regarding 
bone marrow sparing (see Figure 1.). Dose to the crucial OARs 
responsible for dysphagia was also reduced with BM-HT. The 
trade off for this was an slightly increased lung and kidney 
dose. 
 
